Patents by Inventor Phillip Bowen
Phillip Bowen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11236053Abstract: This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.Type: GrantFiled: July 26, 2018Date of Patent: February 1, 2022Assignees: Emory University, Mercer University, Howard University, Union UniversityInventors: Osman Güner, Bernard Lassegue, Kathy Griendling, Qian Xu, David Brown, J. Phillip Bowen, Amol Kulkarni, E. Blake Watkins
-
Publication number: 20200270214Abstract: This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.Type: ApplicationFiled: July 26, 2019Publication date: August 27, 2020Inventors: Osman Güner, Bernard Lassegue, Kathy Griendling, Qian Xu, David Brown, J. Phillip Bowen, Amol Kulkarni, E. Blake Watkins
-
Patent number: 8168657Abstract: The present invention relates to solenopsin A and its analogs for use as angiogenesis inhibitors. The present compounds unexpectedly exhibit good activity as angiogenesis inhibitors, which find use as antitumor/anticancer agents as well as to treat a number of conditions or disease states in which angiogenesis is a factor.Type: GrantFiled: January 24, 2003Date of Patent: May 1, 2012Inventors: J. Phillip Bowen, Jack L. Arbiser, David Whitmire, M. Scott Furness
-
Patent number: 7872029Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: August 22, 2008Date of Patent: January 18, 2011Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Publication number: 20090018167Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: ApplicationFiled: August 22, 2008Publication date: January 15, 2009Applicants: J. Phillip Bowen, Emory UniversityInventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Patent number: 7432303Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: March 8, 2005Date of Patent: October 7, 2008Assignees: James and Emory UniversityInventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Patent number: 7052271Abstract: A draft inducer system has a voltage reducer capable of converting an input AC voltage to a reduced voltage, and an inducer unit capable of being coupled with the voltage reducer. The voltage reducer includes a reducer housing, a set of prongs extending from the reducer housing, and an output interface capable of delivering the reduced voltage. The set of prongs is capable of plugging into an AC outlet. The inducer unit has a unit housing, an air moving device within the unit housing, and a mixing chamber formed by the unit housing. The mixing chamber has an exhaust input to receive exhaust from a burning fuel, and an ambient air input for receiving ambient air. The ambient air mixes with the exhaust in the mixing chamber to produce mixed air. Accordingly, the mixing chamber also has a mix output capable of directing the mixed air from the mixing chamber.Type: GrantFiled: September 4, 2003Date of Patent: May 30, 2006Assignee: Comair Rotron, Inc.Inventors: Fred A. Brown, Phillip Bowen, Jeffrey E. From
-
Publication number: 20050271989Abstract: A draft inducer system has a voltage reducer capable of converting an input AC voltage to a reduced voltage, and an inducer unit capable of being coupled with the voltage reducer. The voltage reducer includes a reducer housing, a set of prongs extending from the reducer housing, and an output interface capable of delivering the reduced voltage. The set of prongs is capable of plugging into an AC outlet. The inducer unit has a unit housing, an air moving device within the unit housing, and a mixing chamber formed by the unit housing. The mixing chamber has an exhaust input to receive exhaust from a burning fuel, and an ambient air input for receiving ambient air. The ambient air mixes with the exhaust in the mixing chamber to produce mixed air. Accordingly, the mixing chamber also has a mix output capable of directing the mixed air from the mixing chamber.Type: ApplicationFiled: August 2, 2005Publication date: December 8, 2005Inventors: Fred Brown, Phillip Bowen, Jeffrey From
-
Patent number: 6906105Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: July 18, 2002Date of Patent: June 14, 2005Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Publication number: 20040129264Abstract: A draft inducer system has a voltage reducer capable of converting an input AC voltage to a reduced voltage, and an inducer unit capable of being coupled with the voltage reducer. The voltage reducer includes a reducer housing, a set of prongs extending from the reducer housing, and an output interface capable of delivering the reduced voltage. The set of prongs is capable of plugging into an AC outlet. The inducer unit has a unit housing, an air moving device within the unit housing, and a mixing chamber formed by the unit housing. The mixing chamber has an exhaust input to receive exhaust from a burning fuel, and an ambient air input for receiving ambient air. The ambient air mixes with the exhaust in the mixing chamber to produce mixed air. Accordingly, the mixing chamber also has a mix output capable of directing the mixed air from the mixing chamber.Type: ApplicationFiled: September 4, 2003Publication date: July 8, 2004Inventors: Fred A. Brown, Phillip Bowen, Jeffrey E. From
-
Publication number: 20030027830Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, incluidng angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: ApplicationFiled: July 18, 2002Publication date: February 6, 2003Applicant: University of Georgia Research Foundation, Inc.Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Patent number: 6462075Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, incluidng angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: December 26, 2000Date of Patent: October 8, 2002Assignees: The University of Georgia Research Foundation, Inc., Emory UniversityInventors: J. Phillip Bowen, Thomas Phillip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Patent number: 6369078Abstract: The present invention relates to solenopsin alkaloid derivatives which are trans-2,6-disubstituted piperidines according to the structure: wherein R1 and R2 are selected from a C1 to C20 saturated or unsaturated linear, cyclic or branch-chained substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted aromatic group, or an ester group. In certain preferred embodiments, where R1 or R2 contains an unsaturated group, such as an alkenyl group, the double bond in the alkenyl group preferably is found in the hydrocarbon chain between the carbon atom bonded to the piperidine ring and the adjacent carbon atom (&agr; and &bgr; carbons).Type: GrantFiled: August 29, 2000Date of Patent: April 9, 2002Inventors: J. Phillip Bowen, M. Scott Furness, David Whitmire
-
Publication number: 20020040029Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: ApplicationFiled: December 26, 2000Publication date: April 4, 2002Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Patent number: 5132322Abstract: Compounds that are analogs of etoposide and exhibit antitumor activity are disclosed. The compounds of the present invention have the following formula: ##STR1## where: R.sub.1 is .beta.-OCH.sub.2 CH.sub.2 NH.sub.2 .beta.-NHCH(CH.sub.3)CH.sub.2 OH, .beta.-NHCH.sub.2 CH(CH.sub.3)OH, .beta.-Cl, .beta.-Br, .beta.-OH, .alpha.-OH, .beta.-NH, .alpha.-NH.sub.2, .beta.-NHCH.sub.2 CH.sub.2 OH, .alpha.-NHCH.sub.2 CH.sub.2 OH, .beta.-NHCH.sub.2 CH.sub.2 CH.sub.3, .beta.-NHCH.sub.2 CH.sub.2 OCH.sub.3, .beta.-NHCH.sub.2 CH.dbd.CH.sub.2, .beta.-NHCH.sub.2 CH(OH)CH.sub.3, .beta.-NHCH.sub.2 CH.sub.2 CH.sub.2 OH, .beta.-OCH.sub.2 CH.sub.2 OH, ##STR2## R.sub.2 is H, or Br; R.sub.1 is H, or Br;R.sub.4 is H, or Br;R.sub.5 is H, or Br; andR.sub.6 is H, or --CH.sub.3.Type: GrantFiled: September 12, 1989Date of Patent: July 21, 1992Assignee: The University of North Carolina at Chapel HillInventors: Kuo-Hsiung Lee, Zhe Oing Wang, J. Phillip Bowen, Dora M. Schnur, Yung-Chi Cheng, Su-Ying Liu, Yao H. Kuo, Masami Mori